The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

Goyvaerts, Cleo; Breckpot, Karine

doi:10.3389/fimmu.2018.02052

Cited by 23 publications

(18 citation statements)

References 179 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These can selectively recognize and kill cancer cells irrespective of their location, and can form an immunological memory, ready to act when cancer cells with the same properties pop up. Activation of CTLs requires tumor antigen presentation in MHC-I molecules and co-stimulation by professional APCs of which DCs have been extensively studied for cancer vaccination 56,159.…”

Section: Therapeutic Application Of Nanobodies and Nanobody Derivativmentioning

confidence: 99%

Theranostics in immuno-oncology using nanobody derivatives

Lecocq

Vlaeminck

Hanssens³

et al. 2019

Theranostics

Self Cite

View full text Add to dashboard Cite

Targeted therapy and immunotherapy have become mainstream in cancer treatment. However, only patient subsets benefit from these expensive therapies, and often responses are short‐lived or coincide with side effects. A growing modality in precision oncology is the development of theranostics, as this enables patient selection, treatment and monitoring. In this approach, labeled compounds and an imaging technology are used to diagnose patients and select the best treatment option, whereas for therapy, related compounds are used to target cancer cells or the tumor stroma. In this context, nanobodies and nanobody-directed therapeutics have gained interest. This interest stems from their high antigen specificity, small size, ease of labeling and engineering, allowing specific imaging and design of therapies targeting antigens on tumor cells, immune cells as well as proteins in the tumor environment. This review provides a comprehensive overview on the state-of-the-art regarding the use of nanobodies as theranostics, and their importance in the emerging field of personalized medicine.

show abstract

Section: Therapeutic Application Of Nanobodies and Nanobody Derivativmentioning

confidence: 99%

Theranostics in immuno-oncology using nanobody derivatives

Lecocq

Vlaeminck

Hanssens³

et al. 2019

Theranostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…An additional platform that could benefit from CDLV technology is in vaccinology, where researchers are developing methods to express antigens in APCs in situ. 10 LV vectors have been investigated extensively for this purpose and it has been shown that a lack of pre-existing immunity allows repeated administrations. 11 However, a potential limitation of LV use for APC transduction is the expression of SAMHD1 (SAM and HD domain-containing deoxynucleoside triphosphate triphosphohydrolase 1) in these immune cells, which lowers intracellular dNTP pools and reduces transduction efficiency by restricting the activity of RT.…”

Section: Discussionmentioning

confidence: 99%

“… 9 Additionally, the possibility to target antigen-presenting cells (APCs) with LV vectors has been explored for vaccine development. 10 , 11 Use of a transient mRNA delivery system in a LV context could offer a significant development in these areas of research, avoiding any issues related to persistence of IDLV or IPLV vector genomes.…”

Section: Introductionmentioning

confidence: 99%

Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation

Counsell

Brabandere

Karda

et al. 2021

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

Lentiviral (LV) vectors based on human immunodeficiency virus type I (HIV-1) package two copies of their single-stranded RNA into vector particles. Normally, this RNA genome is reverse transcribed into a double-stranded DNA provirus that integrates into the cell genome, providing permanent gene transfer and long-term expression. Integration-deficient LV vectors have been developed to reduce the frequency of genomic integration and thereby limit their persistence in dividing cells. Here, we describe optimization of a reverse-transcriptase-deficient LV vector, which enables direct translation of LV RNA genomes upon cell entry, for transient expression of vector payloads as mRNA without a DNA intermediate. We have engineered a novel LV genome arrangement in which HIV-1 sequences are removed from the 5′ end, to enable ribosomal entry from the 5′ 7-methylguanylate cap for efficient translation of the vector payload. We have shown that this LV-mediated mRNA delivery platform provides transient transgene expression in vitro and in vivo . This has a potential application in gene and cell therapy scenarios requiring temporary payload expression in cells and tissues that can be targeted with pseudotyped LV vectors.

show abstract

“…19,22 Interestingly, some of the inherited shortcomings of AV, such as immunity evoked against the AV capsid and low-level expression of AV genes, may now prove beneficial for the development of anticancer immunotherapies, where inducing immunity against cancer or directly killing the cancer cell is the goal. 74,75 The combined immunity against the AV and the short time of expression may prove beneficial for using AV to develop potential vaccines. 76,77 Work with AV vectors is done using BSL-2 practices.…”

Section: Adenovirus Vectorsmentioning

confidence: 99%

Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges

Ghosh

Brown

Jenkins³

et al. 2020

Applied Biosafety

132

113

View full text Add to dashboard Cite

Introduction: National Institutes of Health (NIH) defines gene therapy as an experimental technique that uses genes to treat or prevent disease. Although gene therapy is a promising treatment option for a number of diseases (including inherited disorders, some types of cancer, and certain viral infections), the technique remains risky and is still under study to make sure that it will be effective and safe. Methods: Applications of viral vectors and nonviral gene delivery systems have found an encouraging new beginning in gene therapy in recent years. Although several viral vectors and nonviral gene delivery systems have been developed in the past 3 decades, no one delivery system can be applied in gene therapy to all cell types in vitro and in vivo. Furthermore, the use of viral vector systems (both in vitro and in vivo) present unique occupational health and safety challenges. In this review article, we discuss the biosafety challenges and the current framework of risk assessment for working with the viral vector systems. Discussion: The recent advances in the field of gene therapy is exciting, but it is important for scientists, institutional biosafety committees, and biosafety officers to safeguard public trust in the use of this technology in clinical trials and make conscious efforts to engage the public through ongoing forums and discussions.

show abstract

The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road

Cited by 23 publications

References 179 publications

Theranostics in immuno-oncology using nanobody derivatives

Theranostics in immuno-oncology using nanobody derivatives

Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation

Viral Vector Systems for Gene Therapy: A Comprehensive Literature Review of Progress and Biosafety Challenges

Contact Info

Product

Resources

About